SVCM
JSPR icon

Saturn V Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Saturn V Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-138,622
Closed -$1.09M – 26
2023
Q4 		$1.09M Sell
138,622
-80
-0.1% -$537 0.42% 22
2023
Q3 		$971K Buy
+138,702
New +$1.69M 0.41% 19

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Saturn V Capital Management's JSPR Position: Q1 2024 in Review

Saturn V Capital Management sold out of Jasper Therapeutics (JSPR) in Q1 2024, closing a stake of 138,622 shares — an estimated $1.09M sold.

Saturn V Capital Management first reported a position in JSPR in Q3 2023 and held it in 2 quarters. The position peaked at $1.09M in Q4 2023. 61 funds tracked by Wall St. Rank hold JSPR as of Q1 2024.

  • Saturn V Capital Management reported no remaining Jasper Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Saturn V Capital Management sold 138,622 Jasper Therapeutics shares in Q1 2024, an estimated $1.09M.
  • Saturn V Capital Management first reported a position in Jasper Therapeutics in Q3 2023 and held it in 2 quarters.
  • Saturn V Capital Management's Jasper Therapeutics position peaked at $1.09M in Q4 2023.
  • 61 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2024.

Based on Saturn V Capital Management's 13F filing for Q1 2024, filed 15 May 2024.